Sangamo Therapeutics

10 hours ago
bookmarkBookmark

Sangamo Therapeutics is a company. It is in Brisbane, the United States and its CEO is Alexander D. Macrae. It was founded in 1995 and is part of the Health Care sector, specifically in the Biotechnology industry.

Key facts

plus See more facts
link LinkedIn: 31K followers
link X (Twitter): 4K followers

Extract data

Download datasets about Sangamo Therapeutics:

dataset Dataset of stocks from Sangamo Therapeutics:

Sangamo Therapeutics is one of the companies in Biotechnology, companies in Health Care, companies in Brisbane, companies in the United States and 3,456,835 companies in our database.

Talking Points

  • Sangamo Therapeutics, Inc. | Pioneering Genetic Cures
  • Sangamo uses a multi-platform approach to gene-based therapeutics with industry leading technologies in gene therapy, gene editing, cell therapy and gene regulation.
  • Committed to translating our ground-breaking science into genomic medicines that transform patients’ lives.
  • We're committed to translating our ground-breaking science into genomic medicines that transform patients' lives. | For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Our scientists are leaders in the discovery, research and ...
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

Related

Connected or similar to Sangamo Therapeutics: .

This dashboard is based on data from: YAHOO-FIN, YFINANCE, Twitter.

This content is available under the CC BY 4.0 license.